Oria Meds Review
Semaglutide & tirzepatide GLP-1 weight-loss telehealth · Independently scored 6.6/10
Best for: seeing which pharmacy actually compounds your medication before you buy
Oria Meds's strongest column is the clinical side — which molecules it will prescribe, and how it handles dosing.
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
No insurance needed · Vetted by our editors
Oria Meds sells a compounded GLP-1 program at $149/mo and a compounded dual GIP/GLP-1 program at $249/mo, with free shipping, unlimited clinician access and monthly live expert sessions included. It is one of the few sellers in this register that names its compounding pharmacy in public: PerfectRx of Flower Mound, Texas, with that pharmacy's own address and phone published in the footer. It does not name the molecule in either program, describing them only as compounded GLP-1 and compounded dual GIP/GLP-1.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Vetted alternatives to Oria Meds
Luvo Health
Best for: moving between compounded and brand without changing seller
Editorial score · methodology
Strut Health
Best for: semaglutide at $99/month, 48% under the register median
Editorial score · methodology
Pallas Health
Best for: knowing which pharmacy fills the vial — it names Belmar Pharmacy
Editorial score · methodology
Oria Meds at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide
- Starting price
- $149/mo (Card reads "GLP-1 — Compounded GLP-1 medication — Starting at $149 /per month". The site never names the molecule.)
- Pricing model
- Flat — dose increases don't raise the monthly price
- What's included
- Medication · Consult · Shipping
- FDA status
- No FDA warning letter on record
How Oria Meds scores
Six columns, each one computed from something Oria Meds has published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where it publishes nothing, that absence is what gets scored. Every seller in the register goes through the same six columns.
Value25%
3.0/10The figures published here are not comparable monthly cash prices for the medication — an insured copay, a per-vial rate, a membership fee or a starting-dose teaser. Capped rather than scored against the register.
Effectiveness25%
10.0/10Dispenses semaglutide and tirzepatide, compounded only. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
User Experience15%
8.0/10On the seller's own pages, a price is published before the questionnaire starts.
Trust & Safety15%
6.5/10does not name a dispensing pharmacy; shows a price before asking for health information. Our verification confidence is medium.
Accessibility10%
5.0/10Publishes no list of states served, so coverage cannot be confirmed either way. Capped at the midpoint — this measures disclosure, not reach.
Support10%
7.0/10The price covers medication, consult, shipping.
A seller that will not show a price before an intake loses points on Value and carries that note in its review. Withholding the number is itself a finding. How we score →
What we checked on Oria Meds
Last checked August 2026- Re-read the price on file across 2 dose or plan tiers
- Checked state coverage: all 50
- Established what the monthly figure covers, and what it leaves out
- Searched our FDA enforcement register for this operator
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below. Editorial confidence in this data: medium.
What signing up with Oria Meds involves
Assembled from this seller’s entry in the register — the price record, the state list, the dispensing pharmacy where one is named, and what the monthly figure covers. It describes what a reader can expect to meet on the way to a prescription, and what is missing from the seller’s own disclosures. It is not a clinical judgment and not a prescribing decision.
- 1Oria Meds publishes a price on its own site before asking anything about you. You can compare it against this register without starting a questionnaire.
- 2The intake is a written questionnaire. No live video visit or baseline bloodwork is recorded as required.
- 3Oria Meds does not say which pharmacy dispenses the medication. That is common here and it means you cannot check the pharmacy's record before you buy.
- 4The monthly price is recorded as covering medication, consult, shipping.
- No comparable monthly cash price for the medication is on record — either nothing is published, or what is published is a fee, an insured copay or a per-vial rate rather than a monthly cost.
- No state list is published, so whether Oria Meds serves your state cannot be confirmed from its site.
Oria Meds support, as documented
- support@oriameds.com
Cancelling Oria Meds
Read from what Oria Meds publishes in its own terms. Where a line says the seller does not publish something, that is the finding — we looked and it is not stated. Terms change; check the seller’s current policy before you subscribe.
- Cancel any time
- Yes
- Minimum commitment
- None stated; subscription billing
- Refund policy
- "Prescription medications are not returnable and not refundable once dispensed"
- Early-termination fee
- None
GLP-1 medications Oria Meds offers
Each one has its own guide: how the molecule works, the dosing schedule, the side effects that show up in practice, and what the trials actually measured.
Pricing
Prices re-verified
Card reads "GLP-1 — Compounded GLP-1 medication — Starting at $149 /per month". The site never names the molecule.
Card reads "GLP-1 + GIP — Compounded dual GIP/GLP-1 medication — Starting at $249 /per month". The site never names the molecule.
Check the price yourself before you pay
Every figure here was read off Oria Meds's own checkout on the date shown. Sellers move prices without announcing it, and promotional rates lapse, so confirm the standing cost on their site before committing.
In its favor
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- The monthly price is recorded as flat across doses, so it does not climb as the dose is titrated up
- The monthly figure covers medication, consult, shipping
- No FDA warning letter matched this operator when we searched our enforcement register
Against it
- No state list is on record here, so whether it serves your state cannot be confirmed from this page
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
What Oria Meds charges
Oria Meds charges $149/month, and holds that rate across every dose. That sits at the affordable end of what we track. Flat dose pricing matters more than it reads: on a tiered plan the bill grows as the dose does, which means the figure that persuaded you to sign up is not the figure you end up living with.
- Compounded semaglutide — $149/month
- Compounded tirzepatide — $249/month
Across the GLP-1 providers in our register the median standing price is about $170/month, so Oria Meds is genuinely under the middle rather than merely advertising that it is.
Found, at about $149/month, is the closest thing we track to a like-for-like alternative.
What Oria Meds dispenses
Oria Meds prescribes semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the pair carrying the strongest published outcome data. These are compounded preparations from a licensed pharmacy rather than approved pens, which is where the lower price comes from. A compounded drug is not FDA-approved as a finished product — the specific preparation has not been reviewed for safety, efficacy or manufacturing quality.
What we could verify
On the record: it treats patients in all 50 states. We searched the federal warning-letter record for this operator and came back with nothing. Because the medication is compounded and no dispensing pharmacy is named publicly, the single most useful question to ask at intake is which licensed pharmacy fills the prescription. A seller that will not answer that has told you something. How we weigh oversight, disclosure and price evidence is set out in our scoring methodology.
Who should look elsewhere
- You want the FDA-approved pen specifically. Nothing here is the approved finished product.
- You need to bill insurance. Like most of this market, this is cash-pay.
It fits if
- the lowest standing monthly cost is what you are solving for
- you want the price to stop moving as your dose climbs
- you need access regardless of where you live
Our read
Oria Meds competes on price and does it without an obvious sacrifice elsewhere: $149/month, no warning letter on file, and access that is not unusually restricted.
The Bottom Line
Oria Meds's strongest column is the clinical side — which molecules it will prescribe, and how it handles dosing.
Before you pay Oria Meds
Starting at $149 a month. Check today's price, then book the free consultation.
Where Oria Meds is the wrong choice
No seller in this register suits every reader, and saying otherwise would be the easiest way to sell one. On these four counts another entry does better.
- If you need the FDA-approved pen rather than a compounded vial, consider Found.
- If the standing monthly cost is what decides it, consider Collective (from $59/mo).
- If you want a human checking in, not just a prescription, consider Oak.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
Cited across this Oria Meds review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of September 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
See Oria Meds's current pricing
Plans start at $149 a month. The free consultation is where you learn whether you qualify, and what it costs today.